Newly Approved therapy reduces frequency of Multiple Sclerosis relapses by 54%

Biogen and AbbVie have been granted EU marketing authorization forZinbryta (daclizumab), to treat adult patients with relapsing forms of multiple sclerosis. Relapse frequency per year was shown to be reduced by up to 45% against other treatments, and 54% against placebo.  Read on.